[10-Q] NovelStem International Corp. Quarterly Earnings Report
NovelStem International Corp. filed its Q3 2025 report, showing a swing to profitability driven by non-operating items and significant liability reduction. For the nine months ended September 30, 2025, the company reported net income of $2,469,177 versus a loss a year ago, primarily from relief of indebtedness income of $1,697,024 and a $1,171,760 gain on disposal of its 50% interest in NetCo, which was used to settle a litigation funding liability.
Operating activity remains minimal: administrative fee income was zero and G&A fell to $198,007 from $893,887. Liquidity is tight with cash of $627 and current liabilities of $2,067,209 at September 30, 2025, though these liabilities declined from $5,304,486 after the NetCo transaction. The company disclosed substantial doubt about its ability to continue as a going concern and is pursuing fundraising and potential monetization of former NewStem licenses (up to $3,750,000). It also reported material weaknesses in internal control. Common shares outstanding were 46,881,475 as of November 12, 2025.
- Settled litigation funding liability, eliminating obligations totaling approximately $2.96 million through the NetCo transaction.
- G&A expenses decreased materially to $198,007 for the nine months, improving cash burn versus prior year.
- Substantial doubt about ability to continue as a going concern disclosed.
- Material weaknesses in internal control over financial reporting remain unresolved.
- Very limited liquidity with $627 in cash against $2.07 million in current liabilities at September 30, 2025.
Insights
Profit is non-recurring; liquidity and controls remain weak.
NovelStem posted nine-month net income of
Balance sheet stress persists: cash was
Management cites substantial doubt about going concern and reports material weaknesses in internal control over financial reporting. Future activity hinges on fundraising and potential payments of up to
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
| QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For
the quarterly period ended
| TRANSITION REPORT UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from _________________ to _________________
Commission
file number:
(Exact name of registrant as specified in its charter)
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
| (Address of principal executive offices) | (Zip Code) |
| Registrant’s telephone number, including area code |
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||
| None |
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filed, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large accelerated filer ☐ | Accelerated filer ☐ |
| Smaller
reporting company | |
| Emerging
growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
Indicate the number of shares outstanding of each of the issuer’s classes of common stock, as of the latest practicable date.
| Class | Outstanding at November 12, 2025 | |
| Common
Stock, $ |
NOVELSTEM INTERNATIONAL CORP.
Quarterly Report on Form 10-Q
for the Quarterly Period Ended September 30, 2025
TABLE OF CONTENTS
| PAGE | |
| Part I Financial Information | |
| Item 1. Unaudited Condensed Financial Statements: | |
| Unaudited Condensed Balance Sheets as of September 30, 2025 and December 31, 2024 | 3 |
| Unaudited Condensed Statements of Operations for the nine and three months ended September 30, 2025 and 2024 | 4 |
| Unaudited Condensed Statements of Changes in Shareholders’ Deficit for the nine months ended September 30, 2025 and 2024 | 5 |
| Unaudited Condensed Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 | 6 |
| Notes to Unaudited Condensed Financial Statements | 7 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 15 |
| Item 3. Quantitative and Qualitative Disclosures About Market Risk | 18 |
| Item 4. Controls and Procedures | 18 |
| Part II Other Information | |
| Item 1. Legal Proceedings | 19 |
| Item 1A. Risk Factors | 19 |
| Item 6. Exhibits | 19 |
| Signatures | 20 |
| 2 |
PART I
ITEM 1. UNAUDITED CONDENSED FINANCIAL STATEMENTS
NOVELSTEM INTERNATIONAL CORP.
CONDENSED BALANCE SHEETS
| 2025 | 2024 | |||||||
| As of | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| ASSETS | ||||||||
| Current assets: | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable, administrative fees | - | |||||||
| Prepaid expenses | ||||||||
| Total current assets | ||||||||
| Investment in NetCo | - | |||||||
| Investment in NewStem, net | - | - | ||||||
| Total assets | $ | $ | ||||||
| LIABILITIES AND SHAREHOLDERS’ DEFICIT | ||||||||
| Current liabilities: | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Notes payable, including accrued interest | ||||||||
| Current portion of long-term notes payable, including accrued interest | ||||||||
| Bridge loan payable, related party, including accrued interest | - | |||||||
| Convertible debt, including accrued interest | ||||||||
| Derivative liability, guarantee | - | |||||||
| Total liabilities | ||||||||
| Commitments and contingencies (see Note 7) | - | - | ||||||
| Shareholders’ deficit: | ||||||||
| Common stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Treasury stock, at cost, | ( | ) | ( | ) | ||||
| Total shareholders’ deficit | ( | ) | ( | ) | ||||
| Total liabilities and shareholders’ deficit | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 3 |
NOVELSTEM INTERNATIONAL CORP.
CONDENSED STATEMENTS OF OPERATIONS
(UNAUDITED)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Nine Months Ended | Three Months Ended | |||||||||||||||
| September 30, | September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Administrative fee income | $ | - | $ | $ | - | $ | ||||||||||
| Operating expenses: | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Total operating expenses | ||||||||||||||||
| Loss from operations | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Other (income) expenses: | ||||||||||||||||
| Loss on derivative instrument | - | - | ||||||||||||||
| Gain on disposal of equity method investment | ( | ) | - | - | - | |||||||||||
| Relief of indebtedness income | ( | ) | - | - | - | |||||||||||
| Interest expense | ||||||||||||||||
| Total other (income) expenses | ( | ) | ||||||||||||||
| Income (loss) before income taxes | ( | ) | ( | ) | ( | ) | ||||||||||
| Provision for income tax | - | - | - | - | ||||||||||||
| Income (loss) before equity in net income (loss) of equity method investees | ( | ) | ( | ) | ( | ) | ||||||||||
| Equity in net income (loss) of equity method investees | ( | ) | ( | ) | ||||||||||||
| Impairment of equity method investee, NewStem | ( | ) | ( | ) | ||||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||||
| Basic and diluted net income (loss) per share: | ||||||||||||||||
| Net income (loss) per share - basic | $ | $ | ( | ) | $ | - | $ | ( | ) | |||||||
| Weighted average number of shares outstanding - basic | ||||||||||||||||
| Net income (loss) per share - diluted | $ | $ | ( | ) | $ | - | $ | ( | ) | |||||||
| Weighted average number of shares outstanding - diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 4 |
NOVELSTEM INTERNATIONAL CORP.
CONDENSED STATEMENTS OF SHAREHOLDERS’ DEFICIT
(UNAUDITED)
For the Nine Months Ended September 30, 2025:
| Additional | Number of | Total | ||||||||||||||||||||||||||
| Number of | Common | Paid-In | Accumulated | Treasury | Treasury | Shareholders’ | ||||||||||||||||||||||
| Shares | Stock | Capital | Deficit | Shares | Stock | Deficit | ||||||||||||||||||||||
| Balance, January 1, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Net loss | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||
| Balance, March 31, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Net income | - | - | - | - | - | |||||||||||||||||||||||
| Debt restructuring | ||||||||||||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||
| Balance, June 30, 2025 | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||
| Net loss | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
For the Nine Months Ended September 30, 2024:
| Additional | Number of | Total | ||||||||||||||||||||||||||
| Number of | Common | Paid-In | Accumulated | Treasury | Treasury | Shareholders’ | ||||||||||||||||||||||
| Shares | Stock | Capital | Deficit | Shares | Stock | Deficit | ||||||||||||||||||||||
| Balance, January 1, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Net loss | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||
| Balance, March 31, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Net loss | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||
| Balance, June 30 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Balance | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Net loss | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||
| Net income loss | - | - | - | ( | ) | - | - | ( | ) | |||||||||||||||||||
| Stock-based compensation | - | - | - | - | - | |||||||||||||||||||||||
| Balance, September 30, 2024 | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
| Balance | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 5 |
NOVELSTEM INTERNATIONAL CORP.
CONDENSED STATEMENTS OF CASH FLOWS
(UNAUDITED)
| 2025 | 2024 | |||||||
| Nine Months Ended | ||||||||
| Sept 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash flows from operating activities: | ||||||||
| Net income (loss) | $ | $ | ( | ) | ||||
| Equity in loss of equity method investees | - | |||||||
| Impairment loss, NewStem | ||||||||
| Bad debt expense | ||||||||
| Accretion of discount on note payable | ||||||||
| Gain on derivative instrument | - | |||||||
| Noncash disposal of equity method investment | - | - | ||||||
| Gain on disposal of equity method investment | ( | ) | - | |||||
| Relief of indebtedness income | ( | ) | - | |||||
| Accrued interest added to notes payable and convertible debt | ||||||||
| Stock-based compensation | ||||||||
| Change in operating assets and liabilities: | ||||||||
| Accounts receivable, administrative fees | ( | ) | ||||||
| Prepaid expenses | ||||||||
| Accounts payable | ||||||||
| Accrued expenses | - | |||||||
| Net cash used in operating activities | ( | ) | ( | ) | ||||
| Cash flows from investing activities: | ||||||||
| Loans made | - | ( | ) | |||||
| Net cash used in investing activities | - | ( | ) | |||||
| Cash flows from financing activities: | ||||||||
| Proceeds from issuances of short term notes payable | $ | $ | - | |||||
| Proceeds from convertible debt | - | |||||||
| Proceeds from issuance of long term notes payable | - | |||||||
| Net cash provided by financing activities | ||||||||
| Net change in cash | ( | ) | ( | ) | ||||
| Cash at the beginning of the period | ||||||||
| Cash at the end of the period | $ | $ | ||||||
| Supplemental cash flow information: | ||||||||
| Cash paid during the period for: | ||||||||
| Interest | $ | $ | ||||||
| Supplemental Non-Cash Investing and Financing Activities: | ||||||||
| Interest capitalized to notes payable | $ | $ | - | |||||
| Settlement of long term notes payable | $ | $ | - | |||||
| Settlement of derivative liability, net of interest | $ | $ | - | |||||
The accompanying notes are an integral part of these unaudited condensed financial statements.
| 6 |
NOVELSTEM INTERNATIONAL CORP.
NOTES TO CONDENSED FINANCIAL STATEMENTS
(Unaudited)
NOTE 1—NATURE OF OPERATIONS
Description of Business
NovelStem
International Corp. (“NovelStem” or the “Company”) is a holding company whose principal assets consisted of an
approximate
NewStem focused on the development and commercialization of diagnostic technology that can predict patients’ anti-cancer drug resistance, allowing for targeted cancer treatments and the potential to reduce resistance to chemotherapy.
NetCo is a legacy media business interest which owns “Net Force”, a book publishing franchise.
Going Concern, Liquidity and Management’s Plans
Since
inception, the Company has accumulated a deficit of approximately $
The
Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include
additional financing and fundraising as well as monetization of assets held related to equity method investments as well as potential
merger or buyout transactions. Specifically, the Company sold its interest in NetCo to its joint venture partner in a transaction that
satisfied the related debt (litigation funding agreement). Also, the Company is working with former NewStem management to monetize the
technology of NewStem and has an agreement in place to receive up to $
The
Company has in place a finance agreement with two individuals who are shareholders and directors under which it borrowed $
On May 9, 2025, the Company entered into a Settlement Agreement and Release whereby the investment in NetCo was monetized to settle the litigation funding liability to Omni Bridgeway in full. See Note 8.
In view of the matters described above, the Company’s ability to meet financing requirements is dependent upon the ability to complete additional fundraising or obtain additional financing, and/or monetize the intangible assets of NewStem. These factors, among others, raise substantial doubt about the Company’s ability to continue as a going concern. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts or amounts and classification of liabilities that might be necessary should the Company be unable to continue in existence.
NOTE 2—SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all the information and footnotes required by GAAP for complete financial statements. In the opinion of management, the unaudited condensed financial statements reflect all adjustments, which include only normal recurring adjustments necessary for the fair statement of the balances and results for the periods presented. Certain information and footnote disclosures normally included in the Company’s annual financial statements prepared in accordance with GAAP have been condensed or omitted. These condensed consolidated financial statement results are not necessarily indicative of results to be expected for the full fiscal year or any future period.
The accompanying unaudited condensed financial statements and related disclosures have been prepared with the presumption that users of the unaudited condensed financial statements have read or have access to the audited financial statements for the preceding fiscal year. Accordingly, these unaudited condensed consolidated financial statements should be read in conjunction with the Company’s Form 10-K, which was filed with the United States Securities and Exchange Commission (“SEC”) on April 7, 2025, from which the Company derived the balance sheet data at December 31, 2024.
| 7 |
Certain information and footnote disclosures normally included in condensed financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations for interim reporting. The Company believes that the disclosures contained herein are adequate to make the information presented not misleading. These condensed financial statements should be read in conjunction with the Company’s Form 10-K filed with the Securities and Exchange Commission on April 7, 2025 for the years ended December 31, 2024 and 2023.
Equity Investments
Investee
companies that are not consolidated, but over which the Company exercises significant influence, are accounted for under the equity method
of accounting. Whether or not the Company exercises significant influence with respect to an Investee depends on an evaluation of several
factors, including, among others, representation on
The Company reviewed equity investments for impairment on an annual basis, or earlier if events or changes in circumstances indicate that the carrying amounts might not be recoverable.
The
Company held a minority investment in an entity, NewStem, which was accounted for pursuant to the equity method of accounting until its
dissolution in August 2025. Additionally, until May 9, 2025 the Company was a
Reclassifications
Accrued
interest of $
Derivative Financial Instruments
The
Company had in place a financial instrument, in the form of a note payable, which included an identified embedded derivative in the form
of a guarantee. The identified embedded derivative was bifurcated and accounted for separately. Such derivative financial instruments
are measured at fair value at each financial statement reporting date. If the fair value of a financial liability (the derivative) exceeds
the proceeds received for the issuance of a hybrid instrument in an arm’s length transaction with no rights or privileges that
require separate accounting recognition as an asset identified, then the embedded derivative is recorded at fair value with the excess
of fair value over proceeds recognized as a loss in earnings. During the nine months ended September 30, 2024, the Company recognized
a loss on derivative financial instruments of $
Basic and Diluted Net Income (Loss) Per Share
Basic net income (loss) per share is computed by dividing the net loss by the weighted average number of shares outstanding during the period, excluding treasury stock. Diluted net loss per share is computed by dividing the net loss by the weighted average number of shares outstanding plus the dilutive potential of common shares which would result from the exercise of stock options and warrants. The dilutive effects of stock options and warrants are excluded from the computation of diluted net income (loss) per share if the effect of doing so would be antidilutive.
The following data represents the amounts used in computing earnings per share and the effect on income (loss) and the weighted average number of shares of dilutive potential common stock (unaudited):
SCHEDULE OF AMOUNTS USED IN COMPUTING EARNINGS PER SHARE AND EFFECT ON LOSS AND WEIGHTED AVERAGE NUMBER OF SHARES
| 2025 | 2024 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Net income (loss) attributable to common shareholders | $ | $ | ( | ) | ||||
| Weighted average shares outstanding: | ||||||||
| -Basic | ||||||||
| Basic net income (loss) per share | $ | $ | ( | ) | ||||
| Net income (loss) attributable to common shareholders | $ | $ | ( | ) | ||||
| Effect of dilutive securities: | ||||||||
| Convertible debt, interest | - | |||||||
| Net income (loss) attributable to common shareholders | $ | $ | ( | ) | ||||
| Weighted average shares outstanding: | ||||||||
| -Basic | ||||||||
| Add: Convertible Debt | - | |||||||
| Add: Stock options | - | - | ||||||
| -Diluted | ||||||||
| Diluted net income (loss) per share | $ | $ | ( | ) | ||||
| 8 |
| 2025 | 2024 | |||||||
| Three Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Net income (loss) attributable to common shareholders | $ | ( | ) | $ | ( | ) | ||
| Weighted average shares outstanding: | ||||||||
| -Basic | ||||||||
| Basic net income (loss) per share | $ | - | $ | ( | ) | |||
| Net income (loss) attributable to common shareholders | $ | ( | ) | $ | ( | ) | ||
| Effect of dilutive securities: | ||||||||
| Convertible debt, interest | - | - | ||||||
| Net income (loss) attributable to common shareholders | $ | ( | ) | $ | ( | ) | ||
| Weighted average shares outstanding: | ||||||||
| -Basic | ||||||||
| Add: Convertible Debt | - | - | ||||||
| Add: Stock options | - | - | ||||||
| -Diluted | ||||||||
| Diluted net income (loss) per share | $ | - | $ | ( | ) | |||
Options and warrants excluded from the computation of earnings per share for the nine and three months ended:
SCHEDULE OF OPTIONS AND WARRANTS EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| 2025 | 2024 | |||||||
| September 30, | ||||||||
| 2025 | 2024 | |||||||
Convertible debt | - | |||||||
| Warrants | - | |||||||
| Stock options | ||||||||
| Anti-dilutive securities | ||||||||
NOTE 3—EQUITY METHOD INVESTMENTS
Investment in NewStem
In
2018, the Company entered into a Share Purchase Agreement with NewStem and other related parties to provide aggregate funding of up to
$
The Company accounted for its investment in NewStem under the equity method.
NewStem was a development stage company which incurred losses since its inception and generated only minimal revenues under a licensing agreement. NewStem is liquidated in August 2025.
The
Company assessed its investment in NewStem for impairment on an annual basis or more frequently if indicators of impairment exist. During
the year ended December 31, 2024, indicators of impairment became evident due to the inability of NewStem to raise funds. Due to the
inability to raise funds, NewStem was unable to continue operations and dissolved in August 2025. The intangible assets of NewStem, including license agreements,
have reverted to the licensor, Yissum (the commercial division of Hebrew University). The Company has reached an agreement with Yissum
regarding the potential monetization of these intangible assets which provides for the Company to receive up to $
During
the year ended December 31, 2024, the Company signed an agreement (the “Purchase Agreement”) to acquire the remainder of
NewStem in exchange for shares of Company stock as well as funding for NewStem operations. In anticipation of this transaction, the Company
advanced $
During
the nine and three months ended September 30, 2024, the Company recorded a reimbursement due to NewStem of approximately $
The following table represents the Company’s investment in NewStem:
SCHEDULE OF INVESTMENTS
Nine Months Ended September 30, 2025 | Year Ended December 31, 2024 | |||||||
| (Unaudited) | ||||||||
| Investment in NewStem, beginning | $ | - | $ | |||||
| Allocation of net income (loss) from NewStem | - | ( | ) | |||||
| Investment in NewStem before impairment | - | |||||||
| Impairment loss recorded | - | ( | ) | |||||
| Investment in NewStem, ending | $ | - | $ | - | ||||
| 9 |
The results of operations of the Company’s investment in NewStem is summarized below (unaudited):
SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Condensed income statement information: | ||||||||||||||||
| Net revenues | $ | - | $ | - | $ | - | $ | - | ||||||||
| Gross margin | $ | - | $ | - | $ | - | $ | - | ||||||||
| Net income | $ | - | $ | ( | ) | $ | - | $ | ( | ) | ||||||
| Company’s allocation of net income from NewStem | $ | - | $ | ( | ) | $ | - | $ | ( | ) | ||||||
The financial position of the Company’s investment in NewStem is summarized below:
| 2025 | 2024 | |||||||
| As of | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| Condensed balance sheet information: | ||||||||
| Current assets | $ | - | $ | |||||
| Non-current assets | $ | - | $ | |||||
| Current liabilities | $ | - | $ | |||||
| Non-current liabilities | $ | - | $ | - | ||||
Investment in NetCo
As
of December 31, 2024, NovelStem owned a
The Company accounted for its investment in NetCo under the equity method and recognized nominal royalties and administrative fees from this arrangement. The Company assessed its investment in NetCo for impairment on an annual basis or more frequently if indicators of impairment exist.
The following table represents the Company’s investment in NetCo:
SCHEDULE OF INVESTMENTS
| Nine Months Ended September 30, 2025 | Year Ended December 31, 2024 | |||||||
| (Unaudited) | ||||||||
| Investment in NetCo, beginning | $ | $ | ||||||
| Allocation of net loss from NetCo | ( | ) | ||||||
| Distribution from NetCo | ( | ) | - | |||||
| Sale of ownership interest in NetCo | ( | ) | - | |||||
| Investment in NetCo, ending | $ | - | $ | |||||
The results of operations of the Company’s investment in NetCo is summarized below (unaudited):
SCHEDULE OF OPERATIONS AND FINANCIAL POSITION INVESTMENT
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Condensed income statement information: | ||||||||||||||||
| Net sales | $ | - | $ | $ | - | $ | ||||||||||
| Gross margin | $ | - | $ | $ | - | $ | ||||||||||
| Net income | $ | $ | ( | ) | $ | - | $ | ( | ) | |||||||
| Company’s allocation of net income from NetCo | $ | $ | ( | ) | $ | - | $ | ( | ) | |||||||
The financial position of the Company’s investment in NetCo is summarized below:
| 2025 | 2024 | |||||||
| As of | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| Condensed balance sheet information: | ||||||||
| Current assets | $ | - | $ | |||||
| Non-current assets | $ | - | $ | |||||
| Current liabilities | $ | - | $ | |||||
| Non-current liabilities | $ | - | $ | - | ||||
| 10 |
NOTE 4—NOTES PAYABLE
In
December 2023, the Company entered into two short-term notes payable with unrelated parties, Hewlett Fund and AIGH Investment Partners,
LLC. The notes are for $
Long-term notes payable are summarized as follows:
SCHEDULE OF LONG TERM NOTES PAYABLE
| As of | ||||||||
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| (Unaudited) | ||||||||
| Notes payable related parties: | ||||||||
| Notes payable director and Executive Chairman | $ | $ | ||||||
| Accrued interest added to note balance | ||||||||
| Total notes payable director and Executive Chairman | ||||||||
| Note payable shareholder, principal amount | ||||||||
| Accrued interest added to note balance | - | |||||||
| Less unamortized discount | - | ( | ) | |||||
| Total note payable shareholder | ||||||||
| Note payable, litigation funding agreement: | ||||||||
| Note payable Omni Bridgeway (Fund 4) Invt. 3 L.P. | - | |||||||
| Accrued interest added to agreement balance | - | |||||||
| Total note payable, litigation funding agreement | - | |||||||
| Total notes payable | ||||||||
| Less current portion | ( | ) | ( | ) | ||||
| Long-term notes payable | $ | - | $ | - | ||||
In
May 2022, the Company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a shareholder and member
of the Board, to borrow up to an aggregate of $
On
May 5, 2023, the Company entered into a long-term note payable with a shareholder for $
Note Payable, Litigation Funding Agreement
On
February 11, 2022, the Company entered into a nonrecourse litigation funding agreement (the “Agreement”) with Omni Bridgeway
(Fund 4) Invt. 3 L.P. (“Omni”) related to an arbitration proceeding disclosed in Note 7. The Agreement provided for Omni
to fund all costs related to the arbitration up to $
| 11 |
During
July 2023, the arbitration was settled. As a result of the ruling disclosed in Note 7, the liability became probable and reasonably estimable,
and the Company recorded the full liability due to Omni as of December 31, 2023. This liability consists of expenses funded by Omni of
$
The
Company began negotiations for settlement of this Agreement during 2024 and on May 9, 2025, the Company entered into a Settlement Agreement
and Release with our JV partner in NetCo, C.P. Group, and Omni whereby our interest in NetCo was sold in exchange for funds of $
Bridge Loan
In
February 2025, Jan Loeb, Executive Chairman, began advancing funds to the Company for operating expenses in the form of an interim bridge
loan until alternate funding sources can be found. The Company is accruing interest at
Convertible Debt
In
April 2024, the Company borrowed $
NOTE 5—EQUITY
(a) General
At
September 30, 2025 and December 31, 2024, the Company had issued
(b) Summary Employee Option Information
The
Company’s stock option plan provides for the grant to officers, directors, third party contractors and other future key employees
of options to purchase shares of common stock. The purchase price may be paid in cash or, if the option is “in-the-money”,
it is automatically exercised “net”. In a net exercise of an option, the Company does not require a payment of the exercise
price of the option from the optionee but reduces the number of shares of common stock issued upon the exercise of the option by the
smallest number of whole shares that has an aggregate fair market value equal to or in excess of the aggregate exercise price for the
option shares covered by the option exercised. Each option is exercisable to one share of the Company’s common stock. Most options
expire within nine years from the date of the grant and generally vest on the first anniversary date of their issuance. Pursuant to the
Equity Incentive Plan the Company’s board of directors approved on November 12, 2018, an aggregate of
The Company utilized the Black-Scholes option-pricing model to estimate fair value, utilizing the following assumptions for the options issued during the nine months ended September 30, 2024 (all in weighted averages):
SCHEDULE OF FAIR VALUE OF OPTION USING VALUATION ASSUMPTIONS
| Nine Months Ended | ||||
| September 30, 2024 | ||||
| Risk-free interest rate | % | |||
| Expected term of options, in years | ||||
| Expected annual volatility | % | |||
| Expected dividend yield | % | |||
| Determined weighted average grant date fair value per option | $ | |||
No options were issued during the nine months ended September 30, 2025.
The
expected term of the options represents an estimate of the length of time until the expected date of exercising the options. Options
granted have a maximum life of
| 12 |
(c) Summary Option Information
A summary of the Company’s option plans for the nine months ended September 30, 2025, is presented below (unaudited):
SCHEDULE OF STOCK OPTION ACTIVITIES
| Number | Weighted | |||||||
| of | Average | |||||||
| Options | Exercise | |||||||
| (in shares) | Price | |||||||
| Outstanding, December 31, 2024 | $ | |||||||
| Granted | - | - | ||||||
| Outstanding, September 30, 2025 | $ | |||||||
| Exercisable, September 30, 2025 | $ | |||||||
Stock-based
compensation expense was $
The
total compensation cost related to non-vested awards not yet recognized was approximately $
(d) Warrants
The Company issued warrants at exercise prices equal to or greater than the market value of the Company’s common stock at the date of issuance. A summary of warrant activity follows (unaudited):
SUMMARY OF WARRANTS ACTIVITY
| Number of | Weighted | |||||||
| shares | Average | |||||||
| underlying | Exercise | |||||||
| warrants | Price | |||||||
| Outstanding, December 31, 2024 | $ | |||||||
| Granted | - | - | ||||||
| Exercised | - | - | ||||||
| Forfeited or expired | ( | ) | ||||||
| Outstanding, September 30, 2025 | - | $ | - | |||||
The
warrant agreements were amended on May 12, 2023 to extend the expiration date to
| 13 |
NOTE 6—INCOME TAXES
The Company’s income tax provision differs from the expense that would result from applying statutory rates to income (loss) before taxes. A reconciliation of the provision (benefit) for income taxes with amounts determined by applying the statutory U.S. federal income tax rate to income before income taxes is as follows (unaudited):
SCHEDULE OF INCOME BEFORE INCOME TAXES
| Amount | Tax Rate | Amount | Tax Rate | |||||||||||||
| Nine Months Ended September 30, | ||||||||||||||||
| 2025 | 2024 | |||||||||||||||
| Amount | Tax Rate | Amount | Tax Rate | |||||||||||||
| Computed tax at the federal statutory rate of | $ | % | $ | ( | ) | % | ||||||||||
| State income taxes, net of federal income tax benefit | % | ( | ) | % | ||||||||||||
| Change in federal valuation allowance | ( | ) | ( | )% | ( | )% | ||||||||||
| Permanent difference - relief of indebtedness income | ( | ) | ( | )% | - | % | ||||||||||
| Foreign rate differential | - | % | ( | ) | % | |||||||||||
| Total provision for income tax | $ | - | % | $ | - | % | ||||||||||
| Amount | Tax Rate | Amount | Tax Rate | |||||||||||||
| Three Months Ended September 30, | ||||||||||||||||
| 2025 | 2024 | |||||||||||||||
| Amount | Tax Rate | Amount | Tax Rate | |||||||||||||
| Computed tax at the federal statutory rate of | $ | ( | ) | % | $ | ( | ) | % | ||||||||
| State income taxes, net of federal income tax benefit | ( | ) | % | ( | ) | % | ||||||||||
| Change in federal valuation allowance | ( | )% | ( | )% | ||||||||||||
| Foreign rate differential | - | % | ( | ) | % | |||||||||||
| Total provision for income tax | $ | - | % | $ | - | % | ||||||||||
NOTE 7—COMMITMENTS AND CONTINGENCIES
The
Company was the claimant in an arbitration proceeding against their
As
a result of this ruling, the costs related to the litigation funding agreement disclosed in Note 4 were recognized and a total liability
of $
NOTE 8—SUBSEQUENT EVENTS
The Company evaluated subsequent events through the date these financial statements were available to be issued and filed with the SEC.
In
October 2025, the Company borrowed additional funds totaling $
| 14 |
NOVELSTEM INTERNATIONAL CORP.
| ITEM 2. | MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Statements in the following discussion and throughout this Form 10-Q that are not historical in nature are “forward-looking statements.” You can identify forward-looking statements by the use of words such as “expect,” “anticipate,” “estimate,” “may,” “will,” “should,” “intend,” “believe,” and similar expressions. Although we believe the expectations reflected in these forward-looking statements are reasonable, such statements are inherently subject to risk and we can give no assurances that our expectations will prove to be correct. Actual results could differ from those described in this Form 10-Q because of numerous factors, many of which are beyond our control. We undertake no obligation to update these forward-looking statements to reflect events or circumstances after the date of this Form 10-Q or to reflect actual outcomes.
Overview
We are a development stage company and reported net income (losses) of approximately $2,469,000 and $(3,070,000) for the nine months ended September 30, 2025 and 2024, respectively, and $(77,000) and $(2,464,000), for the three months ended September 30, 2025 and 2024. We had current assets of approximately $15,000 and current liabilities of $2,067,000 as of September 30, 2025. As of December 31, 2024, our current assets and current liabilities were approximately $32,000 and $5,304,000, respectively. The decrease in current liabilities is primarily due to the settlement of our litigation funding agreement with Omni in conjunction with the sale of our JV interest in NetCo.
We have prepared our financial statements for the nine months ended September 30, 2025 assuming that we will continue as a going concern. Our continuation as a going concern is dependent upon our ability to work with Yissum to monetize the former NewStem license agreement and intangible assets and the continuing financial support from our shareholders as well as obtaining additional outside funding. Our sources of capital in the past have included the sale of equity and our equity securities, which include common stock sold in private transactions, large alternative minimum tax refunds, and related party debt as well as debt from unrelated parties.
NewStem was a development stage Israeli biotech limited liability company focused on pioneering intellectual property related to haploid human embryonic stem cells for the development of personalized diagnostics and therapeutics for genetic and epigenetic diseases. NewStem incurred losses related to in process research and development since inception and the Company recorded our percentage allocation of these net losses as incurred. NewStem liquidated in August 2025, and we have recorded a full impairment loss on our investment in NewStem.
RESULTS OF OPERATIONS
The following discussion of our financial condition and results of operations should be read in conjunction with our financial statements and the related notes thereto and other financial information appearing elsewhere in this Form 10-Q. In the discussion below, general and administrative expenses are referred to as “G&A expenses”.
| Nine Months Ended September 30, | Three Months Ended September 30, | |||||||||||||||||||||||
| 2025 | 2024 | Change | 2025 | 2024 | Change | |||||||||||||||||||
| Administrative fee income | $ | - | $ | 9,000 | $ | (9,000 | ) | $ | - | $ | 3,000 | $ | (3,000 | ) | ||||||||||
| Operating expenses: | ||||||||||||||||||||||||
| General and administrative expenses | 198,007 | 893,887 | (695,880 | ) | 39,469 | 566,551 | (527,082 | ) | ||||||||||||||||
| Total operating expenses | 198,007 | 893,887 | (695,880 | ) | 39,469 | 566,551 | (527,082 | ) | ||||||||||||||||
| Loss from operations | (198,007 | ) | (884,887 | ) | 686,880 | (39,469 | ) | (563,551 | ) | 524,082 | ||||||||||||||
| Other (income) expenses: | ||||||||||||||||||||||||
| Gain on derivative instrument | - | 90,000 | (90,000 | ) | - | 115,000 | (115,000 | ) | ||||||||||||||||
| Gain on disposal of equity method investment | (1,171,760 | ) | - | (1,171,760 | ) | - | - | - | ||||||||||||||||
| Relief of indebtedness income | (1,697,024 | ) | - | (1,697,024 | ) | - | - | - | ||||||||||||||||
| Interest expense | 207,672 | 306,742 | (99,070 | ) | 43,711 | 105,336 | (61,625 | ) | ||||||||||||||||
| Total other (income) expenses | (2,661,112 | ) | 396,742 | (3,057,854 | ) | 43,711 | 220,336 | (176,625 | ) | |||||||||||||||
| Income (loss) before income taxes | 2,463,105 | (1,281,629 | ) | 3,744,734 | (83,180 | ) | (783,887 | ) | 700,707 | |||||||||||||||
| Provision for income tax | - | - | - | - | - | - | ||||||||||||||||||
| Income (loss) before equity in net income (loss) of equity method investees | 2,463,105 | (1,281,629 | ) | 3,744,734 | (83,180 | ) | (783,887 | ) | 700,707 | |||||||||||||||
| Equity in net income (loss) of equity method investees | 640 | (159,741 | ) | 160,381 | 300 | (51,578 | ) | 51,878 | ||||||||||||||||
| Impairment of equity method investee, NewStem | 5,432 | (1,628,657 | ) | 1,634,089 | 5,432 | (1,628,657 | ) | 1,634,089 | ||||||||||||||||
| Net income (loss) | $ | 2,469,177 | $ | (3,070,027 | ) | $ | 5,539,204 | $ | (77,448 | ) | $ | (2,464,122 | ) | $ | 2,386,674 | |||||||||
We are a holding company whose primary asset currently is our right to the monetization of the former NewStem license now held by Yissum. We currently conduct no other business and as a result, we have no operating revenue or cost of revenue. We did charge annual administrative fees to an affiliated entity through the year ended December 31, 2024.
The Company incurs G&A expenses primarily related to professional fees, insurance and stock-based compensation. We incurred G&A expenses of approximately $198,000 and $894,000 for the nine months ended September 30, 2025 and 2024, respectively. Specifically, professional fees decreased by approximately $169,000 in the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024, primarily due to a decrease in legal fees and audit fees for NewStem. We incurred a bad debt expense during the nine months ended September 30, 2025 of approximately $9,500 for the write off of uncollectible administrative fees compared to bad debt expense for the write off of notes receivable from NewStem of $500,000 during the nine months ended September 30, 2024. We had reductions in insurance expense and stock compensation of approximately $15,000 and $22,000, respectively. Other miscellaneous G&A expenses increased by approximately $500.
We incurred G&A expenses of approximately $39,000 and $566,000 for the three months ended September 30, 2025 and 2024, respectively. Specifically, professional fees decreased by approximately $21,000 in the three months ended September 30, 2025 as compared to the three months ended September 30, 2024, primarily due to a decrease in legal fees and audit fees for NewStem. We had reductions in stock compensation of approximately $9,000. We incurred a bad debt expense for the write off of notes receivable from NewStem of $500,000 during the three months ended September 30, 2024. And other miscellaneous G&A expenses increased by approximately $3,000 during the three months ended September 30, 2025 as compared to the three months ended September 30, 2024.
| 15 |
Interest expense decreased by approximately $99,000 and $62,000 in the nine and three months ended September 30, 2025 as compared to the nine and three months ended September 30, 2024 due to the settlement of the Omni litigation funding agreement.
The Company has recorded no income tax expense as we have incurred operating losses until the current period during which loss carryforwards are being utilized and all deferred tax assets are fully offset by an income tax valuation allowance.
We reported net income from equity method investees during the nine and three months ended September 30, 2025 which consists of income from NetCo of $640 and $300, respectively.
We reported net losses from equity method investees during the nine and three months ended September 30, 2024 which included losses from NetCo of $4,164 and $1,244 and losses from NewStem of $155,577 and $50,334, respectively.
We reported impairment expense of $1,628,657 related to our investment in NewStem in the nine and three months ended September 30, 2024 and a reduction or recovery of impairment expense related to cash received in the liquidation of NewStem of $5,432 in the nine and three months ended September 30, 2025.
Liquidity and Capital Resources
We have not paid dividends on our common stock since our name change and business focus shift in 2018. Our present policy is to apply cash to potential acquisitions; consequently, we do not expect to pay dividends on common stock in the foreseeable future.
The Company will need to obtain additional funds to continue its operations. Management’s plans with regard to these matters include fundraising until our interest in NewStem’s technology is profitable. Although management continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient cash from financing on terms acceptable to the Company, or that NewStem’s technology will be monetized and become profitable.
In May 2022, the Company entered into note agreements with Jan Loeb, our Executive Chairman and Jerry Wolasky, a member of the Board, to borrow up to an aggregate of $600,000 for working capital needs. The note agreements were amended in March 2024 to increase the total borrowing to $650,000 and extend the maturity date. The agreements provide for interest at a rate of 10% per annum and mature September 1, 2025. As of the date of this Quarterly Report, the full amount of $650,000 has been funded pursuant to these agreements.
During the year ended December 31, 2023, the Company entered into a note agreement with a shareholder to borrow $300,000 for continued working capital. This note bore interest at zero percent (0%) and matured on May 5, 2025. The note included a guarantee which was identified as an embedded derivative with a fair value of a liability of $650,000 at December 31, 2024. This note was amended in May 2025 to provide for fixed interest, remove the guarantee and extend the maturity date to September 30, 2025. This note was amended for a second time in October 2025 to extend the maturity date to December 31, 2026.
In December 2023, the Company entered into two short-term notes payable with unrelated parties for a total of $250,000 in borrowings utilized for the funding of NewStem. The notes bear interest at 12% per annum and mature December 21, 2025, at which time all principal and accrued interest are due and payable. The note agreements include a provision whereby, in the event of a capital raise transaction by the Company, the note holders would be entitled to participate in the transaction in an amount equal to 133% of the amounts owed on the note agreements at the closing of the transaction.
| 16 |
In April 2024, the Company borrowed $100,000 from unrelated parties pursuant to convertible debt agreements accounted for as debt.
During the nine months ended September 30, 2025, the Company borrowed $135,980 from the executive chairman in the form of an interim bridge loan until alternate funding sources can be found. The Company is accruing interest at 10% per annum for these advances.
On May 9, 2025 the Company sold its interest in NetCo to its JV partner for $1,300,000 which was paid directly to Omni in full settlement of all liabilities related to the litigation funding agreement totaling $2,959,625.
Net Cash Used In Operating Activities.
For the nine months ended September 30, 2025, net cash used in operating activities was approximately $141,000, which consisted primarily of net income of approximately $2,469,000, offset by noncash disposal of equity method investment of approximately $1,171,000, relief of indebtedness income of approximately $1,697,000, stock-based compensation of approximately $9,000, accretion of discount on notes payable of approximately $60,000 and interest added to notes payable of approximately $146,000. Additionally, cash was used in operations related to decrease in current assets of approximately $11,000 and a net increase in total accrued liabilities and accounts payables of approximately $32,000.
For the nine months ended September 30, 2024, net cash used in operating activities was approximately $233,000, which consisted primarily of a net loss of approximately $3,070,000, offset by noncash equity in loss of equity method investees of approximately $160,000, accretion of discount on notes payable of approximately $133,000, stock based compensation of approximately $31,000 and interest added to notes payable of approximately $78,000 and reduced by gain on derivative instrument of $90,000. Additionally, cash was used in operations related to an increase in current assets of approximately $9,000 and an increase in accrued liabilities and other payables of approximately $207,000.
Net Cash Used In Investing Activities.
During the nine months ended September 30, 2024, $250,000 was loaned to NewStem in an investing activity. For the nine months ended September 30, 2025, no net cash was used in investing activities.
Net Cash Provided By Financing Activities.
For the nine months ended September 30, 2025, net cash provided by financing activities was approximately $136,000, consisting of short-term borrowings from the executive chairman.
For the nine months ended September 30, 2024, net cash provided by financing activities was $375,000, consisting of long-term borrowings from two directors and a significant stockholder totaling $275,000 and short term borrowings of $100,000.
| 17 |
| ITEM 3. | QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK |
This section is not applicable.
| ITEM 4. | CONTROLS AND PROCEDURES |
Our Principal Executive Officer and Chief Financial Officer conducted an evaluation of our controls and procedures. We have identified material weaknesses in our internal control and procedures and internal control over financial reporting. If not remediated, our failure to establish and maintain effective disclosure controls and procedures and internal control over financial reporting could result in material misstatements in our financial statements and a failure to meet our reporting and financial obligations, each of which could have a material adverse effect on our financial condition and the trading price of our common stock.
Maintaining effective internal control over financial reporting and effective disclosure controls and procedures are necessary for us to produce reliable financial statements. We have re-evaluated our internal control over financial reporting and our disclosure controls and procedures and concluded that they were not effective as of September 30, 2025 and we concluded there was a material weakness in the design of our internal control over financial reporting as it relates to insufficient resources to employ proper segregation of duties over the processing of transactions and financial reporting.
A material weakness is defined as a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim financial statements will not be prevented or detected on a timely basis.
Changes in Internal Control Over Financial Reporting
There was no change in our internal control over financial reporting (as such term is defined in Rule 13a-15(f) under the Exchange Act) during the period covered by this report that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.
| 18 |
PART II
| ITEM 1. | LEGAL PROCEEDINGS |
The Company has no ongoing legal proceedings.
| ITEM 1A. | RISK FACTORS |
We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information under this item.
| ITEM 2. | UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
| (a) | Not applicable. | |
| (b) | Not applicable. | |
| (c) | Not applicable. |
| ITEM 3. | DEFAULTS UPON SENIOR SECURITIES |
Not applicable.
| ITEM 4. | MINE SAFETY DISCLOSURES |
Not applicable.
| ITEM 5. | OTHER INFORMATION |
None.
| ITEM 6. | EXHIBITS |
| #10.13 | 1st Amendment to Promissory Note issued to Stephen Gans | |
| #10.14 | Bridge Note issued to Jan Loeb | |
| #10.15 | 2nd Amendment to Promissory Note issued to Stephen Gans | |
| #31.1 | Certification of Principal Executive Officer and Executive Chairman pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| #31.2 | Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. | |
| #32.1 | Certification of Principal Executive Officer and Executive Chairman pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| #32.2 | Certification of Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. | |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |
| # | This exhibit is filed or furnished herewith. |
| 19 |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this registration statement to be signed on its behalf by the undersigned, thereunto duly authorized.
| NOVELSTEM INTERNATIONAL CORP. | ||
| Date: November 12, 2025 | By: | /s/ Jan Loeb |
| Name: | Jan Loeb | |
| Title: | Executive Chairman | |
| 20 |
FAQ
What were NovelStem (NSTM) Q3 2025 year-to-date results?
What drove NovelStem’s profit in 2025?
How is NovelStem’s liquidity position?
Did NovelStem settle the litigation funding agreement?
What are the key risks disclosed by NovelStem (NSTM)?
Does NovelStem have potential future inflows from NewStem assets?
How many shares are outstanding for NovelStem (NSTM)?
